Thermo Fisher launches Gibco VaxEvo medium for adenovirus vaccine production

Thermo Fisher Scientific has launched Gibco VaxEvo CD 293 Medium, a chemically defined cell culture medium designed to support suspension HEK293 cell growth and adenovirus production.

The animal origin-free medium is intended for human and animal health vaccine developers using suspension-based HEK293 manufacturing processes.

Thermo Fisher said VaxEvo CD 293 Medium is designed to support workflows from early process development through scale-up and manufacturing.

The product is available in liquid and AGT formats.

Suspension HEK293 cells are widely used in adenovirus and adenoviral vector manufacturing, where developers require consistent cell growth and high viral productivity while maintaining scalable production processes.

VaxEvo CD 293 Medium is intended to simplify upstream workflows by supporting adenovirus production without requiring a dedicated feed.

In laboratory benchmarking studies using HEK293 cells, the medium produced average adenovirus type 5 titres comparable with selected competing media.

Thermo Fisher said titres were as much as 5.7 times higher in some comparisons with benchmark products used alongside their recommended feeding strategies.

Alex Cherkassky, Vice President and General Manager of Thermo Fisher Scientific’s cell culture business, said manufacturing considerations begin during early process development and can influence subsequent scalability and operational complexity.

He said the company developed VaxEvo CD 293 Medium as a purpose-built option for suspension-based adenovirus production using HEK293 cells.

The chemically defined formulation is designed to reduce reliance on animal-derived components while supporting greater consistency and manufacturing readiness.

Thermo Fisher said the medium can be used across adenovirus production, vaccine process development, scale-up and manufacturing applications.

The company will offer VaxEvo CD 293 Medium in liquid format and multiple AGT package sizes.



Related Topics and Keywords

, , , , , , , , , , , , , , , , , , , ,

Subscribe to our FREE newsletter and WEBINAR UPDATES

We will not sell or give your information to a third party. See our Privacy Policy